Interview with Aristides Torres Velasco, CEO, Vanquish Mexico
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Address: Blvd, Adolfo Ruiz Cortines No. 4249, Piso 2 Col. Jardines de la Montana C.P. 14210, Mexico
Tel: 01 800 6334 4505
Web: http://www.vanquish.com.mx/
Laboratorios Vanquish was started in 2003 and as a young company has successfully patented one active molecule for Mexico, the United States, and Europe, while also manufacturing and developing generics in the fields of CNS, cardiovascular, oncology and gynaecology. With a strong portfolio in both the public and private market in Mexico, Vanquish is moving forward and now exporting selected products to the United States, and also has manufacturing operations with a partner company in Brazil.
CNS, cardiovascular, oncology, gynaecology, and dietary supplements
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…
Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare…
During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando Cruz, qualified as “reasonably good” considering the impacts…
The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout…
While Mexico struggles with its COVID-19 vaccination campaign, residents of the country’s northern states have begun flying to the United States in search of a shot. Fearful of “fake vaccines”…
Last Wednesday, the lower chamber of the Mexican Congress approved a bill that would legalise recreational marijuana. With a population of nearly 130 million people, Mexico would join Canada and…
The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by Western companies, and AMLO’s call for…
See our Cookie Privacy Policy Here
